The Global Contraceptive Drugs and Devices Market was projected to grow at a CAGR of 7.5% during the forecast period (2018-2023). China being the world’s most-populated country has a population count of about 1.36 billion and has one of the highest rate of contraceptives usage.
Unintended Pregnancies Growing at a Faster Pace
Not using of the contraceptives or the incorrect use of the contraceptives may result in unintended pregnancies and the number of unintended pregnancies percentage is higher in the teens younger than 18 years, followed by the age group of 20-24 years. In the United States, the proportion of pregnancies that were unintended increased slightly between 2001 and 2008 (from 48% to 51%), but, by 2011 it decreased to 45%. And in 2014, these contraceptives have helped women to avoid 2 million unintended pregnancies, which would likely have resulted in 900,000 unplanned births and nearly 700,000 abortions. However, over past few years the awareness on contraception has contributed to both decline in unplanned pregnancies and also growth in the usage of the contraceptives market.
There are also other factors which are accelerating the growth of the contraceptives market is the increasing incidence of the STDs and the rapid increase in the population. The government initiatives are also promoting the use of contraceptives to avoid the unnecessary births and the health benefits from using the contraceptives have also been significant players in the growth of this market.
High Cost of Devices & Treatment
The high costs of the IUD devices have been a barrier for many of the women’s as IUDs are very expensive primarily because of the procedures involved which is known as implanting. The normal cost to insert or remove IUD is around USD 150 to USD 250, depending on the service. The IUD choice of method may not be chosen often because of the cost, which acts as a major restrain to the market growth.
The other major reason for the high cost is the relative length of the efficacy of the IUDs and as they last for a longer duration for years so their cost tends to be higher. There are also other factors such as religious and cultural opposition in certain emerging nations and the fear of certain issues such as infertility resulting from the use of contraceptives have been major setbacks from the market point of view which have been restraining the growth of this market.
North America Holds the Largest Position in the Market
In North America, over 90% of the female population uses the modern contraceptive techniques. The use of contraceptives is the highest in North America, whose share is estimated to be 75.4%. Following North America, Europe is the second largest market globally and the preference of the contraceptives generally varies by region.
Key Developments in the Market
- November, 2017: Teva Pharmaceuticals has signed an agreement with CooperSurgical which will acquire PARAGARD (intrauterine copper contraceptive).
- July 2017: Teva Pharmaceutical launched Vagifem1 (estradiol vaginal inserts), 10 mcg in the United States.
The major players includes- Bayer Healthcare, Pfizer, Merck & Co., Teva Pharmaceuticals Ltd., Agile Therapeutics, Actavis Plc, Ani Pharmaceuticals Inc., Church & Dwight Co. Inc., Fuji Latex Co. Ltd and Johnson & Johnson Ltd. amongst others.
Reasons to Purchase this Report
- Current and future contraceptive drugs and devices market outlook in the developed and emerging markets
- Analyzing various perspectives of the market with the help of Porter’s five forces analysis
- The segment that is expected to dominate the market
- Regions that are expected to witness fastest growth during the forecast period
- Identify the latest developments, market shares and strategies employed by the major market players.
- 3 months analyst support along with the Market Estimate sheet in excel.
Customization of the Report
- This report can be customized to meet your requirements. Please connect with our analyst, who will ensure you get a report that suits your needs.
1.1 MARKET DEFINITION
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. KEY INFERENCES
5. MARKET OVERVIEW
5.1 CURRENT MARKET SCENARIO
5.2 PORTER'S FIVE FORCES ANALYSIS
5.2.1 BARGAINING POWER OF SUPPLIERS
5.2.2 BARGAINING POWER OF CONSUMERS
5.2.3 THREATS OF NEW ENTRANTS
5.2.4 THREAT OF SUBSTITUTE PRODUCT AND SERVICES
5.2.5 COMPETITIVE RIVALRY WITHIN THE INDUSTRY
6. DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES ANALYSIS (DROC)
6.1 MARKET DRIVERS
6.1.1 INCREASING INCIDENCE OF THE STDS
6.1.2 INCREASING RATE OF UNINTENDED PREGNANCIES
6.1.3 EFFECTIVE CONTRACEPTION AND LESS SIDE EFFECTS OF IUCD
6.1.4 RISE IN GOVERNMENT INITIATIVES
6.2 MARKET RESTRAINTS
6.2.1 HIGH COST OF DEVICES & TREATMENT
6.2.2 STRINGENT REGULATORY AND REIMBURSEMENT POLICIES
6.2.3 RELIGIOUS AND CULTURAL OPPOSITION TOWARDS IUDs
6.4 KEY CHALLENGES
7. MARKET SEGMENTATION
7.1 SEGMENTATION-BY CONTRACEPTIVE METHOD
7.1.5 INTRAUTERINE DEVICE (IUD)
7.1.6 MALE CONDOMS
7.1.7 VAGINAL BARRIER METHODS
7.2 BY MODE OF DELIVERY
7.2.1 ORAL CONTRACEPTIVES
7.2.2 TOPICAL CONTRACEPTIVES
7.2.3 CONTRACEPTIVE INJECTABLE
7.3 BY DEVICE
7.3.3 CERVICAL CAPS
7.3.5 VAGINAL RINGS
7.4 BY GENDER
7.5 SEGMENTATION-BY GEOGRAPHY
7.5.1 NORTH AMERICA
22.214.171.124 UNITED STATES
126.96.36.199 UNITED KINGDOM
188.8.131.52 REST OF EUROPE
184.108.40.206 AUSTRALIA & NEW ZEALAND
220.127.116.11 SOUTH KOREA
18.104.22.168 REST OF ASIA-PACIFIC
7.5.4 MIDDLE EAST & AFRICA
22.214.171.124 SOUTH AFRICA
126.96.36.199 REST OF THE MIDDLE EAST & AFRICA
7.5.5 SOUTH AMERICA
188.8.131.52 REST OF SOUTH AMERICA
8. COMPETITIVE LANDSCAPE
8.1 MERGERS & ACQUISITION ANALYSIS
8.2 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS
8.3 NEW PRODUCTS LAUNCHES
9. KEY PLAYERS
9.1 BAYER HEALTHCARE
9.3 MERCK & CO.
9.4 TEVA PHARMACEUTICALS, LTD.
9.5 AGILE THERAPEUTICS
9.6 ACTAVIS PLC
9.7 ANI PHARMACEUTICALS, INC.
9.8 CHURCH & DWIGHT, CO. INC.
9.9 FUJI LATEX CO., LTD
9.10 JOHNSON & JOHNSON, LTD
10. FUTURE OF THE MARKET